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Abstract
A novel function for the binder of Arl two (BART) molecule in pancreatic cancer cells is reported. BART inhibits invasiveness
of pancreatic cancer cells through binding to a Ca
2+-dependent, phosphorylated, guanosine triphosphatase (GTPase)
membrane fusion protein, annexin7 (ANX7). A tumor suppressor function for ANX7 was previously reported based on its
prognostic role in human cancers and the cancer-prone mouse phenotype ANX7(+/2). Further investigation demonstrated
that the BART–ANX7 complex is transported toward cell protrusions in migrating cells when BART supports the binding of
ANX7 to the protein kinase C (PKC) isoform PKCa. Recent evidence has suggested that phosphorylation of ANX7 by PKC
significantly potentiates ANX7-induced fusion of phospholipid vesicles; however, the current data suggest that the BART–
ANX7 complex reduces PKCa activity. Knocking down endogenous BART and ANX7 increases activity of PKCa, and specific
inhibitors of PKCa significantly abrogate invasiveness induced by BART and ANX7 knockdown. These results imply that
BART contributes to regulating PKCa activity through binding to ANX7, thereby affecting the invasiveness of pancreatic
cancer cells. Thus, it is possible that BART and ANX7 can distinctly regulate the downstream signaling of PKCa that is
potentially relevant to cell invasion by acting as anti-invasive molecules.
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Introduction
The binder of Arl two (BART) molecule is a soluble 19-kDa
protein originally purified from bovine brain and identified as a
binding partner of ADP-ribosylation factor-like 2 (ARL2) [1]. The
binding of BART to ARL2 is of high affinity and dependent on the
binding of GTP to ARL2 [1]. Distinct functions have been
inferred from findings that ARLs lack the biochemical or genetic
activities characteristic of ADP ribosylation factors (ARFs), despite
the 40% to 60% amino acid sequence identity between ARFs and
ARLs [2]. ARL2 has been implicated as a regulator of microtubule
dynamics and folding [3], but its function remains largely
unknown. We previously reported that regulation of BART
post-transcriptional modification via intracellular CD24 binding to
G3BP in stress granules contributes to inhibition of invasion and
metastasis of pancreatic ductal adenocarcinoma (PDAC) cells [4].
N-terminal G3BP contributes to post-transcriptional regulation of
BART [5]. Further study demonstrated that BART decreases
invasiveness of PDAC cells by inhibiting the ARL2-mediated
decrease in the activity of the Rho GTPase protein RhoA [6].
These data suggest that BART plays a role in inhibition of PDAC
invasiveness.
ANX7 is a member of the annexin family of calcium-dependent
phospholipid binding proteins and codes for a Ca
2+-activated
GTPase. ANX7(+/2) knockout mice have Ca
2+-dependent
endocrine secretory defects [7]. ANX7 is phosphorylated by
PKC, which significantly enhances binding of ANX7 to fused
phospholipid vesicles in chromaffin cells [8]. Activated PKCs
induce the secretion of MMP-9, lead to activation of MMP-2,
downregulate TIMP-1 and TIMP-2 secretion, and increase MT1-
MMP on the cell surface [9]. Thus, ANX7 may be one of the
factors associated with the PKC-dependent secretion cascade.
Furthermore, ANX7 is a newly described tumor suppressor gene
for prostate cancer, as evidenced by loss of heterozygosity and
reduced ANX7 protein expression in a large fraction of archived
metastatic tumors [10]. ANX7 exhibits many biological and
genetic properties of a tumor suppressor gene and is also
implicated in carcinogenesis through discrete signaling pathways
involving other tumor suppressors, DNA-repair and apoptosis-
related genes [10,11]. These reports have suggested that ANX7
plays several different roles involved in exocytosis, tumor
suppression and carcinogenesis.
PKC is a family of serine/threonine kinases involved in the
transduction of signals, including the Ras signal, for cell
proliferation and differentiation [12,13]. The PKC family consists
of at least 12 isoforms with different tissue expression patterns,
substrate specificities, and subcellular localizations that are related
to specialized cell functions, including cell proliferation, differen-
tiation, and apoptosis [14]. The ‘classical’ PKCs (a, b1, b2, and c)
bind phorbol esters and are Ca
2+ dependent. The ‘novel’ PKCs (d,
e, g, and h) do not depend on Ca
2+, but do bind phorbol esters.
The third subfamily comprises the ‘atypical’ PKCs (j, i, l, and m),
which do not bind to either Ca
2+ or phorbol ester [14,15].
Constitutively activated cell surface receptors, such as the EGF
receptor or the PDGF receptor [16], or Ras [17], cause
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kinase (MAPK) cascade. Overexpression of PKCd induces a more
malignant pancreatic cancer cell phenotype in vivo, through
modulation of cell proliferation and survival [18]. Another study
demonstrated that activated PKC induces lamellipodia formation
and subsequent increased migratory activity of subconjunctival
fibroblasts [19]. Thus, it has been suggested that PKCs induce cell
proliferation/survival, invasion and metastasis.
In this study, ANX7 was identified as a novel binding partner of
BART, and BART was found to be associated with ANX7-PKC
complex formation in PDAC cells. Furthermore, the current
results demonstrated that knocking down BART induces cell
invasion by increasing PKCa activity through the loss of ANX7-
PKCa complex formation. Thus, decreased active PKCa via both
BART and ANX7 contributes to inhibition of PDAC invasiveness.
Results
BART binds to ANX7 in PDAC cells
BART knockdown increases retroperitoneal invasion and
PDAC cell metastasis to liver in an orthotopic xenograft model,
as described in a previous report [4]. To investigate the
mechanism by which BART suppresses invasiveness and metas-
tasis, immunoprecipitation (IP) experiments were performed in the
human PDAC cell line S2-013 using a specific antibody to BART,
to detect complexes of BART with other proteins. S2-013 is a
cloned subline of a PDAC cell line (SUIT-2) derived from a liver
metastasis [20], and was obtained from Dr. T. Iwamura (Miyazaki
Medical College, Miyazaki, Japan). Silver-stained immunoprecip-
itated fractions separated on SDS-PAGE gels revealed a 50-kDa
band that was not seen in the isotype control immunoprecipitates
(arrow in Fig. 1A). The band was excised and analyzed by Q-
TOF-MS after in-gel trypsin digestion, and identified as ANX7.
The peptide sequence coverage was 15% (Fig. 1B). This specific
binding of ANX7 to BART was demonstrated by co-IP from S2-
013 cells (Fig. 1C) and subcellular colocalization was analyzed by
immunostaining of S2-013 cells (Fig. 1D). BART and ANX7
coimmunoprecipitated and were colocalized in the cytoplasm. Of
note is that BART and ANX7 accumulated in lamellipodial-like
protrusions that are essential for cell migration (arrows in Fig. 1E).
ANX7 inhibits PDAC cell invasion
Previously, cell clones were generated in which BART was
stably suppressed by vector-based specific short hairpin small
interfering RNA (siRNA) in S2-013 cells that formerly expressed
high levels of BART [4]. To determine the function of BART-
ANX7 complexes, a wound-healing immunostaining assay was
used to observe the localization of BART and ANX7 in polarized
migrating cells (Fig. 2A). Both BART and ANX7 were recruited to
the leading edges during wound healing of control S2-013 cells
(arrows in Fig. 2A). Depletion of BART inhibited ANX7
accumulation at the leading edges (lower panels in Fig. 2A).
Combined with the result of Fig. 1E, these results indicate that
BART and ANX7 interdependently localize at the leading edges
and in the lamellipodial-like protrusions associated with cell
migration.
In vitro assays were used to examine the effects of ANX7 on cell
motility and invasion. As shown by Western blot analysis, ANX7
expression was markedly reduced in S2-013 and a PDAC cell line,
PANC-1, 72 h after transfection with the ANX7-targeting siRNA
oligonucleotides, in contrast to cells transfected with scrambled
siRNA-oligonucleotides (Fig. 2B). Suppression of ANX7 enhanced
motility in transwell motility assays of S2-013 and PANC-1 as
compared to control cells (Fig. 2C). In two-chamber invasion
assays, ANX7 RNAi cells were significantly more invasive than the
control S2-013 and PANC-1 cells (Fig. 2D). These results suggest
an important role for the binding of BART and ANX7 in
inhibition of cell migration.
Binding of ANX7 and phosphorylated PKC is associated
with inhibiting invasiveness of PDAC cells
Co-IP of the ANX7 and PKC complex was performed using
anti-ANX7 or anti-PKC antibody (10800) reacting with the
PKCa, b1, b2, d, e and g isoforms in S2-013 cells. Immunoblot-
ting of the immunoprecipitates revealed that ANX7 co-immuno-
precipitated with PKC (Fig. 3A). PKC expression was not
particularly high, but there were significant amounts in ANX7-
immunoprecipitated complexes without PKC secretagogues. The
effects of knocking down ANX7 on regulating PKC activity were
investigated using Western blotting using an anti-phospho-PKC
antibody (9379), which detects the classical PKCs (a, b1, b2 and c)
and novel PKCs (d, e, g and h) when phosphorylated at a residue
homologous to Thr514 of PKCc (Fig. 3B). ANX7 knockdown
induced phosphorylation of PKC in S2-013 cells, indicating that
ANX7 plays a role in decreasing phosphorylated PKC. To
investigate the subcellular colocalization of ANX7 and phosphor-
ylated PKC, S2-013 cells were immunostained. ANX7 and
phosphorylated PKC were colocalized in lamellipodial-like
protrusions (arrows in Fig. 3C). Interestingly, ANX7 and
phosphorylated PKC were recruited and colocalized to the
leading edges during wound healing of S2-013 cells (arrows in
Fig. 3D), indicating that phosphorylated PKC is associated with
the anti-invasive function of ANX7. Since ANX7 could function in
decreasing PKC activity (Fig. 3B), ANX7-dependent inhibition of
cell invasion is likely to be associated with decreased activity of the
specific classical or novel PKC isoforms. Thus, further experiments
for analysis of the BART-ANX7-associated inhibition of cell
invasion were focused on the classical and novel PKC isoforms to
which the anti-phospho-PKC antibody (9379) reacted.
Phosphorylated PKC induces cell invasion of PDAC cells
A PKC stimulator, phorbol 12-myristate 13-acetate (PMA) is a
potent tumor promoter [21] that induces migration of subcon-
junctival fibroblasts [19] and glioblastoma cells [9]. PMA interacts
with and activates both classical and novel PKC isoforms [21].
Therefore, the effect of PMA on cell invasion of S2-013 and
PANC-1 was investigated. Immunoblotting using anti-phospho-
PKC antibody (9379) revealed that treatment with PMA increased
active PKCs (Fig. 4A). PMA significantly stimulated cell invasion
of S2-013 and PANC-1 in in vitro invasion assays (Fig. 4B),
indicating that PMA-sensitive PKC isoforms contribute to the
invasiveness of PDAC cells. To confirm that PMA-induced
invasion was dependent on active PKCs, cells were initially
treated with a PKC inhibitor (calphostin C, an inhibitor of both
classical and novel PKCs) and then treated with PMA. Initial
treatment with the PKC inhibitor prevented the PMA-induced
increase in PKC activity (Fig. 4A) and inhibited PMA-mediated
cell invasion of S2-013 and PANC-1 (Fig. 4B). These results
indicate that specific isoforms of classical and novel PKCs could
induce PDAC cell invasion.
Cell-cell adhesion can also influence motility [22]. Upon
formation of cell-cell contacts, cells reduce their migration rate
and cell-surface protrusion activity, and decrease their microtubule
and actin-filament dynamics [23]. To determine the effect of the
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incubated with PMA and immunofluorescence was performed
using anti-E-cadherin and anti-b-catenin antibodies (Fig. 4C).
PMA significantly reduced junction proteins at regions of cell-cell
contact, indicating decreased peripheral localization of junction
proteins, resulting in adherence junctions with decreased stability.
These results suggest that PMA-sensitive PKCs play a role in
decreasing stability of cell-cell contacts and, in turn, inducing cell
invasion.
BART supports the binding of ANX7 to active PKC and
functions in decreasing active PKC
To determine the effect of the BART-ANX7 complexes on
regulating activity of PKC, the effects of BART knockdown on
ANX7 affinity for constitutively activated PKCs by treatment with
PMA were investigated (Fig. 5A). PMA stimulation caused
significant increases in the amount of ANX7-PKC complexes in
control cells, while there were no differences in BART RNAi S2-
013 cells. Furthermore, whether binding could be inhibited by
Figure 1. BART binds to ANX7 in lamellipodial-like protrusions. A. Immunoprecipitates from S2-013 cells using normal rabbit IgG (control)
and anti-BART antibody were examined by silver stain analysis. Q-TOF-MS analysis investigated a prominent band in the BART immunoprecipitates
(arrow). B. Percent coverage for ANX7 is represented by the identified peptides in the total protein sequence (accession number NM_004034). C.
Immunoprecipitated endogenous BART or ANX7 from S2-013 were examined by Western blotting using anti-BART and anti-ANX7 antibodies. Normal
rabbit or mouse IgG was used as an isotype control for BART and ANX7, respectively. D. Immunocytochemical staining of S2-013 cells using anti-BART
(green) and anti-ANX7 (red) antibodies. Blue, DAPI staining. Bar, 10 mm. E. Arrows indicate that BART (green) and ANX7 (red) colocalize at
lamellipodial-like protrusions of S2-013 cells. Blue, DAPI staining. Bar, 10 mm.
doi:10.1371/journal.pone.0035674.g001
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assessed. Calphostin C and chelerythrine chloride (an inhibitor of
PKCa, b, c and d) markedly decreased ANX7-PKC interaction in
PMA-stimulated control cells (Fig. 5A). In addition, BART
immunoprecipitated with increased amounts of ANX7 when S2-
013 cells were treated with PMA, and preincubation with
Figure 2. ANX7 suppresses cell motility and invasion in PDAC cells. A. Negative scrambled control (Scr-1) and BART RNAi (siBART-1) S2-013
cells in confluent cultures were wounded. After 4 h, the cells were immunostained using anti-BART (green) and anti-ANX7 (red) antibodies. Blue, DAPI
staining. Arrows, colocalized BART and ANX7 at the leading edge of control cells. Bars, 10 mm. B. siRNA oligonucleotides targeting ANX7 (siANX7) and
negative scrambled control were transiently transfected into S2-013 and PANC-1 cells. Western blotting validated ANX7 knockdown in both cell lines.
C. Transwell motility assay of cells treated as in (B). Migrated cells in four fields per group were counted. Data are representative of three independent
experiments. Columns, mean; bars, SD. *p,0.005 compared with control cells. D. Quantification of the two-chamber invasion assay of cells treated as
in (B). Invaded cells in four fields per group were counted. Data are representative of three independent experiments. Columns, mean; bars, SD.
*p,0.001 compared with control cells.
doi:10.1371/journal.pone.0035674.g002
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ANX7 or PKC from S2-013 cells. Immunoprecipitates were examined by Western blotting using anti-ANX7 and anti-PKC antibodies. Normal mouse or
rabbit IgG was used as the isotype control for ANX7 or PKC, respectively. B. Western blot with anti-PKC and anti-phospho-PKC antibodies showing S2-
013 cells transiently transfected with siRNA for ANX7 as compared to cells transfected with scrambled control. C. Immunocytochemical staining in S2-
013 cells, as determined with anti-ANX7 (green) and anti-phospho-PKC (red) antibodies. Blue, DAPI staining. Arrows, colocalized ANX7 and
phosphorylated PKC at lamellipodial-like protrusions. Bar, 10 mm. D. Confluent S2-013 cells were wounded. After 4 h, the cells were immunostained
using anti-ANX7 (green) and anti-phospho-PKC (red) antibodies. Blue, DAPI staining. Arrows, colocalized ANX7 and phosphorylated PKC at the
leading edge. Bar, 10 mm.
doi:10.1371/journal.pone.0035674.g003
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nocytochemical analysis was performed to examine the intracel-
lular localization of PMA-induced ANX7-PKC complexes in
control and BART RNAi S2-013 cells (Fig. 5C). ANX7
colocalized with PMA-stimulated PKCs in control cells (arrows
in Fig. 5C); however, BART knockdown prevented binding of
ANX7 and PMA-stimulated PKCs (arrowheads in Fig. 5C). In
addition, IP experiments using anti-phosphorylated PKC antibody
(9379) confirmed that knocking down BART inhibited binding of
ANX7 and phosphorylated PKC (Fig. 5D, E).
BART RNAi S2-013 cells had elevated active PKC levels and
unchanged steady state levels of PKCs (Fig. 5F). This result
indicates that BART may be associated with decreased levels of
active PKC. We hypothesize that BART regulates interactions
between ANX7 and active forms of target PKCs as a scaffold
molecule and/or a cargo protein of ANX7, allows ANX7 to
decrease target PKC activity, and in turn, inhibits cell invasion.
PKC activity is not directly regulated by ANX7
To investigate the role of PKC in regulating phosphorylation of
ANX7, as previously reported in chromaffin cells [8], S2-013 and
PANC-1 cells were metabolically labeled with [
32P]-orthophos-
phoric acid, and then stimulated with PMA. The radioactively
labeled-ANX7 was immunoprecipitated with anti-ANX7 mono-
clonal antibody and was analyzed by phosphor imaging (Fig. 6A).
If ANX7 is a substrate of specific PKCs, the level of ANX7
phosphorylation should result in significantly increased changes in
response to PMA. However, PMA stimulation did not increase the
levels of ANX7 phosphorylation in either cell line. Next, in vitro
phosphorylation assays were used to determine whether PKC
activity was directly regulated by ANX7 (Fig. 6B). Purified rat
brain, with a purity of .95% and containing classical and novel
PKC isoforms, was incubated with recombinant ANX7 protein
with or without recombinant BART protein. ANX7 did not
change the activity of PKCs and adding BART protein was not
Figure 4. Effect of PMA on PDAC cell invasion. A. S2-013 and PANC-1 cells pretreated with or without calphostin C were treated with PMA, and
PKC activity was assessed by Western blotting with an anti-phospho-PKC antibody. B. S2-013 and PANC-1 cells treated as in (A) were plated on
Matrigel invasion chambers. Invaded cells in four fields per group were counted. Data are representative of three independent experiments. Columns,
mean; bars, SD. *p,0.001; **p,0.003 as compared to non-treated control cells. C. S2-013 cells were treated with or without PMA, and
immunocytochemical staining was performed using anti-E-cadherin and anti-b-catenin antibodies (green). Blue, DAPI staining; bars, 10 mm.
doi:10.1371/journal.pone.0035674.g004
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35674Figure 5. Effect of BART on regulating PKC activity through ANX7. A. Immunoprecipitation of PKC from control and BART RNAi S2-013 cells
stimulated by PMA with or without pretreatment of calphostin C or chelerythrine chloride was examined by Western blotting using anti-ANX7 and
anti-PKC antibodies. *, co-immunoprecipitated ANX7 with PKC in BART RNAi S2-013 cells. B. Immunoprecipitation of BART from S2-013 cells treated
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ANX7 is not a substrate of PKC, and that ANX7 does not change
phosphorylation levels of the target PKCs directly.
PKCa is associated with BART-ANX7 complexes
To identify specific isoforms of PKC that bind to ANX7 in this
system, a precise expression profile of classical and novel PKCs
was generated by Western blotting using individual anti-phospho-
PKC antibodies in BART RNAi cells derived from S2-013
(Fig. 7A). Since phosphorylation levels of target PKCs were
increased in BART RNAi cells (Fig. 5F), upregulated phospho-
PKCs in BART RNAi cells were selected for further analysis.
Among these, PKCa was significantly activated by BART
knockdown in S2-013. In addition, PKCa was abundantly
phosphorylated in ANX7 RNAi cells of S2-013 and PANC-1
(Fig. 7B). Next, binding of ANX7 with phosphorylated PKCa was
demonstrated by immunoprecipitation and Western blotting
analysis in S2-013 cells (Fig. 8A). Phospho-PKCg was not
immunoprecipitated with ANX7. To investigate the subcellular
colocalization of phosphorylated PKCa, S2-013 cells were
immunostained. Phosphorylated PKCa was localized in lamelli-
podial-like protrusions (arrows in Fig. 8B). Additionally, ANX7
and phosphorylated PKCa were recruited to the leading edges
during wound healing of control S2-013 cells (upper panels in
Fig. 8C). Depletion of BART did not induce accumulation of
ANX7 at the leading edges and subsequent colocalization with
phosphorylated PKCa (lower panels in Fig. 8C). These results
indicate that PKCa is interdependently associated with BART and
ANX7 in modulating PDAC cell migration.
Specific inhibitors of PKCa inhibit increased cell
migration by knockdown of BART and ANX7
To examine whether PKCa signaling is involved in increased
migration by BART or ANX7 knockdown in S2-013, a PKCa/b1
inhibitor Ro-32-0432 and a specific PKCa inhibitor safingol were
applied in in vitro invasion assays. As shown in Fig. 9A and 9B,
phosphorylated PKCa was specifically decreased by Ro-32-0432
and safingol treatment, but expressions of phospho-PKCg was not
changed. The greatest migration of S2-013 cells occurred after
knocking down BART or ANX7; however, the increased
migration was inhibited by preincubation with Ro-32-0432
(Fig. 9C) and safingol (Fig. 9D). Increased invasiveness by BART
or ANX7 knockdown was not prevented by preincubation with a
myristoylated pseudosubstrate PKCg inhibitor (Fig. 9E) and a
PKCd inhibitor (rottlerin; data not shown). These results suggest
that activation of PKCa is required for PDAC cell migration
induced by BART or ANX7 knockdown.
Discussion
PDAC is one of the deadliest cancers due to its ability to
extensively invade surrounding tissues and metastasize at an early
stage [24]. Extensive local infiltration and metastasis are the main
causes of death in PDAC [25]. In light of the role of BART in
inhibiting PDAC cell invasion, this study was designed to identify
the BART binding proteins associated with PDAC cell invasive-
ness. The salient features of this report are as follows:
(i) BART and ANX7 may function together in complex to
inhibit cell migration.
as in (A) was examined by Western blotting using anti-ANX7 and anti-BART antibodies. C. Immunocytochemical staining of control (upper panels)
and BART RNAi (lower panels) S2-013 cells stimulated by PMA using anti-PKC (green) and anti-ANX7 (red) antibodies. Blue, DAPI staining. Arrows,
ANX7 colocalized with PMA-sensitive PKCs in control cells; arrowheads, PMA-sensitive PKCs not colocalized with ANX7 in BART RNAi cells. Bars,
10 mm. D. Immunoprecipitation of phosphorylated PKC from control and BART RNAi S2-013 cells was examined by Western blotting using anti-ANX7
and anti-phospho-PKC antibodies. E. Densitometric analysis of the results of Figure 5D. The level of ANX7 in the precipitates was assessed after
normalizing ANX7 signals to phospho-PKC signals of cell lysates. F. Western blot with anti-BART and anti-phospho-PKC antibodies showing two S2-
013 clones transfected with siRNA for BART (siBART-1 and 2) as compared to mock (Neo-1) and scrambled (Scr-1) control clones.
doi:10.1371/journal.pone.0035674.g005
Figure 6. PKC phosphorylation is not directly regulated by ANX7. A. S2-013 and PANC-1 cells were prelabeled with [
32P]-orthophosphoric
acid and stimulated or not with PMA. ANX7 was immunoprecipitated, separated by SDS-PAGE, and analyzed by autoradiography. An immunoblot
was performed on the cell lysate as a loading control. B. In vitro phosphorylation assays to investigate the effect of BART and ANX7 on PKC-
phosphorylation. Purified rat brain was incubated with recombinant ANX7 with or without recombinant BART. The reaction products were analyzed
by an ELISA assay. ABS on Y-axis means absorbance at 492 nm as reference measured with a microplate reader.
doi:10.1371/journal.pone.0035674.g006
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active PKC at leading edges.
(iii) Phosphorylated PKCa is responsible for the increased
invasiveness of PDAC cells seen with BART or ANX7
knockdown. PKCa is interdependently associated with
BART and ANX7 in modulating invasiveness of PDAC
cells.
Frequent loss of ANX7 expression was observed in prostate
cancer, especially in metastasis and local recurrence of hormone
refractory disease [7]. Whereas null ANX72/2 mice die during
embryogenesis, ANX7 heterozygous mice (ANX7+/2) develop,
mature, and age normally, and more interestingly, have a cancer-
prone phenotype [10]. A broad range of spontaneous tumors have
been detected in ANX7+/2 mice, including in liver, prostate,
endometrium, salivary gland, and thymus [11]. In the mouse,
haploinsufficiency of ANX7 expression appears to drive progres-
sion to cancer because of genomic instability through a discrete
signaling pathway involving other tumor suppressor genes, DNA-
repair genes, and apoptosis-related genes. Our data suggest that
BART and ANX7 play a role in decreasing the phosphorylation
level of PKCa in PDAC cells. In vitro experiments failed to
demonstrate that ANX7 directly decreased activity of PKC
(Fig. 6B); however, Fig. 6A shows definitively that ANX7 was
not a substrate for PKC in PDAC cells. Although the mechanism
by which ANX7 regulates PKC activity remains unknown, it is
notable that BART and ANX7 could function together to
decrease the activity of the PKCa isoform and, in turn, suppress
invasiveness of PDAC cells. This study enabled evaluation of a
cellular signaling pathway regulated by the ANX7 tumor
suppressor gene in PDAC. Further studies are needed to
determine which molecules directly suppress PKCa, and to
identify precise substrates of PKCa, in order to understand the
mechanisms involved in BART-ANX7-mediated inhibition of cell
invasion.
The role of PKCa in PDAC cell migration has not been
extensively studied. Several lines of evidence indicate that PKCa
plays critical roles in cell proliferation/migration/invasion,
including human poorly differentiated hepatic cancer [26],
endometrial cancer [27] and gastric cancer [28]. Cell signaling
pathways involving the PKC family are initiated by binding of a
ligand, such as a growth factor, to its respective cell surface
receptor, which triggers the breakdown of phospholipids by
phospholipases C and D and production of diacylglycerol (DAG).
DAG binds to and activates most PKC isoforms, which then
translocate to specific subcellular compartments that vary
depending on the PKC isoform and cell type. Ultimately, MAPKs,
including the extracellular-signal-regulated protein kinase (ERK),
c-jun N-terminal kinase (JNK), and p38MAPK, play a crucial role
in cell migration mediated by PMA-activated PKCs [19,29]. That
BART and ANX7 abrogate phosphorylation of ERK in PDAC
cells has been demonstrated (data not shown), suggesting that
PKCa may be associated with modulating the ERK activity
possibly associated with BART-ANX7-related inhibition of
invasiveness. Furthermore, it is possible that PKCa-induced
exocytosis modulates cell migration. Thus, future studies of PKCa
are warranted to further characterize its exocitic function and
elucidate its potential contribution to cell migration.
In summary, the findings presented in this study are supportive
of the pivotal roles of BART in the coordinated regulation of
PKCa activity via binding with ANX7. The functional significance
of the association of BART, ANX7 and PKCa in modulating
invasiveness of PDAC cells was established. It is possible that
BART and ANX7 can distinctly regulate the downstream
Figure 7. The activity of PKCa is increased by suppression of BART and ANX7. A. Western blot with antibodies against the classical and
novel PKC isoforms showing two S2-013 clones transfected with siRNA for BART as compared to mock and scrambled control clones. B. siRNA
oligonucleotides targeting ANX7 and negative scrambled control were transiently transfected into S2-013 and PANC-1 cells. Western blot with
antibodies against the classical and novel PKC isoforms was performed.
doi:10.1371/journal.pone.0035674.g007
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acting as anti-invasive molecules. Further studies to investigate
precise mechanisms of action are warranted.
Materials and Methods
Reagents and antibodies
PMA and PKC inhibitors (calphostin C, chelerythrine chloride,
Ro-32-0432, safingol, rottlerin and a myristoylated pseudosub-
strate PKCg inhibitor) were purchased from Calbiochem (San
Diego, CA). PMA and the PKC inhibitors were prepared as
10 mM stock solutions in dimethyl sulfoxide or distilled water.
Rabbit anti-BART antibody (10090-2-AP) was purchased from
ProteinTech (Chicago, IL). Monoclonal antibodies against ANX7
(610669), Rac1 (610650) and b-catenin (610154) were obtained
from BD Transduction Laboratory (Palo Alto, CA). Polyclonal
antibodies against pan-PKC (sc-10800), PKCa (sc-208), PKCb1
(sc-209), PKCb2 (sc-210), PKCd (sc-213), PKCe (sc-214) and
PKCg (sc-215) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). The rabbit anti-phospho-pan-PKC antibody
(9379) was purchased from Cell Signaling (Grand Island, NY), and
an anti-phospho-PKCa antibody (ab23513) was obtained from
Abcam (Cambridge, MA). Polyclonal antibodies against phospho-
PKCb1 (sc-101776), -PKCd (sc-101777), and -PKCe (sc-12355)
were purchased from Santa Cruz Biotechnology, and polyclonal
antibodies against phospho-PKCb2 (07-873) and -PKCg (07-877)
were obtained from Millipore (Billerica, MA).
Cell culture
The human PDAC cell line S2-013, a subline of SUIT-2, was
obtained from Dr. T. Iwamura [20]. The human PDAC cell line
PANC-1 was obtained from ATCC. Cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco-BRL,
Figure 8. BART supports the colocalization of ANX7 and phospho-PKCa at the leading edges of migrating cells. A.
Immunoprecipitation of ANX7 (left panels) or phospho-PKCa (right panels) from S2-013 cells was examined by Western blotting using antibodies
against ANX7, phospho-PKCa and phospho-PKCg. B. Immunocytochemical staining in S2-013 cells, as determined with anti-phospho-PKC antibody
(green). Blue, DAPI staining. Arrows, phosphorylated PKC at lamellipodial-like protrusions. Bar, 10 mm. C. Confluent cultures of control and BART RNAi
S2-013 cells were wounded. After 4 h, the cells were immunostained using anti-ANX7 (green) and anti-phospho-PKCa (red) antibodies. Blue, DAPI
staining. Bars, 10 mm.
doi:10.1371/journal.pone.0035674.g008
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PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e35674Figure 9. PKCa is associated with increased cell invasion by knockdown of BART and ANX7. A. BART RNAi S2-013 cells and S2-013 cells
transiently transfected with ANX7-siRNA were pretreated with or without Ro-32-0432. The activity of PKCa and g was assessed by Western blotting.
B. Cells shown in (A) were pretreated with or without safingol. The activity of PKCa and PKCg was assessed by Western blotting. C. The effect of Ro-
32-0432 on cell invasion was investigated using the transwell invasion assay. Migrated cells in four fields per group were counted. Data are
representative of three independent experiments. Columns, mean; bars, SD. *p,0.001 compared with non-treated cells. D. The effect of safingol on
cell invasion was investigated using the transwell invasion assay. Data are representative of three independent experiments. Columns, mean; bars, SD.
*p,0.001; **p,0.003 compared with non-treated cells. E. The effect of rottlerin and pseudosubstrate PKCg inhibitor on cell invasion was
investigated using the transwell invasion assay. Data are representative of three independent experiments. Columns, mean; bars, SD.
doi:10.1371/journal.pone.0035674.g009
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serum (FCS) at 37uC in a 5% CO2, humid atmosphere.
Immunoprecipitation and mass spectrometric analysis of
BART
S2-013 cells were lysed in lysis buffer [20 mM HEPES (pH 7.4),
100 mM KCl, 5 mM MgCl2, 0.5% Triton X-100, and protease
inhibitor cocktail tablets (Roche, Penzberg, Germany)]. Equal
amounts of S2-013 cell lysates were incubated with 2 mg of anti-
BART antibody or normal rabbit IgG (isotype control) and
protein G Sepharose. Co-immunoprecipitated proteins were
separated on a 4% to 20% gradient SDS-PAGE and then silver
stained. Bands precipitated by the anti-BART antibody were
excised, digested with trypsin and analyzed using a Q-TOF
Ultima tandem mass spectrometer (Waters, Milford, MA) with
electrospray ionization. Database searches of the acquired MS/
MS spectra were performed using MASCOT v1.9.0 (Matrix
Science, Boston, MA).
In vivo binding of BART with ANX7
S2-013 cells were lysed with lysis buffer and immunoprecip-
itated with 2 mg of anti-BART or anti-ANX7 antibody. To
examine the interaction of endogenous BART with ANX7,
immune complexes were analyzed by Western blotting with
anti-BART and anti-ANX7 antibodies.
Confocal immunofluorescence microscopy
Cells were fixed with 4% paraformaldehyde, permeabilized with
0.1% Triton X-100, covered with blocking solution (3% BSA/
PBS), and then incubated with the primary antibody for 1 h. Alexa
488 and Alexa 594-conjugated secondary antibodies (Molecular
Probes, Carlsbad, CA) were used. Each specimen was visualized
using a Zeiss LSM 510 META microscope (Carl Zeiss, Gottingen,
Germany).
siRNA-expressing constructs and the generation of stable
cell lines
The methods used were as previously reported [4]. We used a
pSUPERgfp vector (OligoEngine, Seattle, WA) for expression of
siRNA. The target sequences for the scrambled negative control
and for BART were 59-TTCTCCGAACGTGTCACGT-39 and
59-CATGGCAGCCTTCACCACA-39, respectively. S2-013 and
PANC-1 cells were transfected with either empty Neo-pSU-
PERgfp, a scrambled oligo-pSUPERgfp negative control, or a
plasmid designed to express siRNA to BART, using FuGENE6
(Roche), according to the manufacturer’s instructions. Cells were
selected in medium containing 500 mg/mL of geneticin to
generate stable pSUPERgfp cell lines. Western blotting was
performed to analyze the protein levels of the single clones.
siRNA treatment
RNAi targeting ANX7 and scrambled negative control siRNA
oligonucleotides were purchased from Santa Cruz Biotechnology
(29690 and 37007). For assays to examine the effect of siRNAs on
ANX7 expression, S2-013 and PANC-1 cells that express ANX7
were plated in six-well plates. After 20 h, the cells were transfected
with 80 pmols of siRNA in siRNA transfection reagent (Santa
Cruz), following the manufacturer’s instructions.
Transwell motility assay
Cells (3.0610
4) were plated in the upper chamber of BD
BioCoat Control Culture Inserts (24-well plates, 8 mm pore size;
Becton Dickinson, San Jose, CA). Serum-free culture medium was
added to the upper chamber, and medium containing 5% FCS
was added to the lower chamber. Cells were incubated on the
membranes for 12 h, and motility was quantified.
Matrigel invasion assay
The two-chamber invasion assay was used to assess cell invasion
(24-well plates, 8 mm pore size, membrane coated with a layer of
Matrigel extracellular matrix proteins; Becton Dickinson). Cells
(4.0610
4) were seeded in serum-free medium into the upper
chamber and allowed to invade toward 5% FCS (the chemoat-
tractant) in the lower chamber. After 20 h incubation, the number
of invading cells at the bottom of the membrane was estimated
under microscopic observation by counting three independent
visual fields.
BART or ANX7 RNAi S2-013 cells were preincubated for
30 min in serum-free medium containing 250 nM Ro-32-0432,
10 mM safingol, 5.0 mM rottlerin, or 5.0 mM myristoylated PKCg
pseudosubstrate inhibitor. These preincubated cells were used in
the two-chamber invasion assay to assess cell invasion.
Wound healing immunostaining assay
A wound in the form of a cross was made through a confluent
cell monolayer with a plastic pipette tip and cells were then
allowed to polarize and migrate toward the wound. After 4 h, cells
were immunostained with primary antibody and then incubated
with fluorophore-conjugated secondary antibodies as described
above. Each specimen was visualized with a Zeiss LSM 510
META microscope.
Stimulation of PKC by PMA and inhibition of kinase
activity by specific inhibitors
Cells were incubated in FCS-free medium for 24 h. 1 h prior to
incubation with PMA, cells were preincubated at 37uCi nC a
2+-
free buffer A [25 mM Hepes (pH 7.2), 118 mM NaCl, 4.2 mM
KCl, 1.2 mM MgCl2, 10 mM NaHCO3, 10 mM glucose, 0.1%
bovine serum albumin] containing 50 nM calphostin C or 1.0 mM
chelerythrine chloride, both specific PKC inhibitors. Next, cells
were cultured for 30 min at 37uC in the presence of 100 nM PMA
in buffer B (buffer A with 2.2 mM CaCl2 added). These cells were
subjected to further analysis.
[
32P]-orthophosphoric acid labeling and treatment of
PDAC cells with PMA and PKC inhibitors
Cells (2610
6/dish, 60 mm) were labeled with [
32P]-orthophos-
phoric acid (1.0 mCi/ml) in phosphate-free Eagle’s minimal
essential medium containing 10% dialyzed FCS for 3 h at 37uC.
The cells were washed once with buffer A. The cells were
pretreated for 1 h at 37uC with or without the PKC inhibitors
50 nM calphostin C or 1.0 mM chelerythrine chloride in buffer A
and were then stimulated to secrete by incubation for 30 min at
37uC in the presence (or absence) of 100 nM PMA in buffer B.
Recombinant ANX7
The entire coding sequence of ANX7 cDNA was amplified by
RT-PCR. The product was subsequently inserted into the pIEx-7
Ek/LIC vector (Novagen, Madison, WI) to produce a fusion
protein, bearing an N-terminal 6-histidine tag. Sf9 cells (Novagen)
were transiently transfected using the Insect GeneJuice Transfec-
tion Reagent (Novagen), according to the manufacturer’s
instructions. Transfected cells were lysed in CytoBuster Protein
Extraction Reagent (Novagen) and centrifuged at 15,0006 g for
15 min. The supernatant was combined with the Ni-NTA His-
Bind Resin (Novagen), and bound proteins were eluted. Western
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the fractions containing ANX7. The fractions, corresponding to
apparently pure proteins, were pooled, and dialyzed against
storage buffer that consisted of 20 mM HEPES (pH 7.4), 20 mM
KCl, and 10% glycerol. The samples were stored at 280uC.
In vitro detection of PKC phosphorylation
A 0.05 unit (0.035 mg) of purified rat brain, with a purity of
.95% and containing classical and novel PKC isoforms
(Calbiochem) was incubated at 30uC for 20 min with 0.5 mmol
of recombinant ANX7 with or without 0.3 mmol recombinant
BART in a final volume of 30 ml of reaction buffer [25 mM Tris-
HCl (pH 7.0), 5 mM b-mercaptoethanol, 3 mM MgCl2,2m M
CaCl2, 1 mM EGTA, 0.5 mM EDTA, 0.1 mM ATP, 50 mg/ml
phosphatidylserine]. To determine PKC phosphorylation, the
reaction products were analyzed by an ELISA assay using
PKLight Protein Kinase Assay kits (Lonza, Basel, Switzerland)
according to the manufacturer’s instructions.
Statistical analysis
The significance of differences between groups was determined
using the Student’s t-test, the Mann-Whitney U test, or Fisher’s
exact test, as appropriate. Differences having P values ,0.05 were
considered statistically significant.
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